RESUMO
· AIM:To investigate the effects and safety of intravitreal injection of Conbercept combined with macular grid pattern photocoagulation for macular edema secondary to non-ischemic branch retinal vein occlusion (BRVO).· METHODS:A total of 38 patients (38 eyes) with macular edema following non-ischemic BRVO were retrospectively analyzed.All patients were given best corrected visual acuity(BCVA),intraocular pressure,slit lamp with preset lens,optic coherent tomography(OCT) and fluorescence fundus angiography (FFA) examination.The BCVA and central macular thickness (CMT) were observed before and 1wk,1,2,3,6,9 and 12mo after treatment.The change in pre-treatment and post-treatment were compared,and the related complications were recorded.· RESULTS:BCVA before treatment and 1wk,1,2,3,6,9 and 12mo after treatment were 0.89±0.62,0.64±0.59,0.55±0.62,0.46±0.43,0.53±0.67,0.43±0.38,0.42±0.29,0.40 ± 0.30,the difference was statistically significant between that before and after treatment (P＜0.001),while the BCVA after treatment showed no significant difference with each other (P＞ 0.05).CMT were 683.25 ± 236.47,298.65±116.12,276.89±107.28,281.55±99.62,251.41 ± 119.47,240.58±88.62,231.74±75.36,209.51±84.68pm,the difference was statistically significant between that before and after treatment (P＜ 0.001),while the those after treatment showed no significant difference with each other (P＞ 0.05).There were 11 eyes received one injection,18 eyes with two injections,2 eyes with 3,3 eyes with 4,and 4 eyes more than 4,the average injection was 2.01±1.42.The CMT decreased after every injection.The intraocular hypertension and other complications were not seen after treatment.· CONCLUSION:Intravitreal injection of conbercept combined with macular grid pattern photocoagulation for macular edema to non-ischemic BRVO can reduce the macular edema and improve BCVA,which is effective and safety.
RESUMO
@#AIM: To investigate the efficacy of intravitreal ranibizumab or conbercept combined with macular laser grid photocoagulation(MLG)for macular edema secondary to branch retinal vein occlusion(BRVO).<p>METHODS: Totally 120 patients(120 eyes)with BRVO were randomized into three groups, 40 patients(40 eyes)in each group. Group A received MLG alone; Group B: intravitreal injection of ranibizumab 0.05mL/0.5mg; Group C: intravitreal injection of conbercept 0.05mL/0.5mg. MLG were performed in Group B and Group A at 1wk after injection. At 1mo after injection, all the patients were examined with fundus fluorescein angiography and optical coherence tomography, repeated injections were given if necessary. Repeated injection rate of Group B and C was compared after a six-month follow-up. before and at 1wk, 1, 3, 6mo after treatment, best corrected visual acuity(BCVA)and central macular thickness(CMT)of the two groups were analyzed.<p>RESULTS: In Group B, there were 4 eyes with 2 consecutive injections, 7 eyes with 3 consecutive injections, and the repeated injection rate was 27.5%. Patients in Group C received injection only once. The repeated injection rate of Group B was higher than that of Group C with significant difference(<i>P</i><0.05). BCVA of the three groups were improved after treatment, CMT was less than those before treatment. BCVA of Group B and C after treatment was better than those of Group A and CMT was less. BCVA of Group C was better than that of Group B, and CMT was less without significant difference(<i>P</i>>0.05). After the follow-up, there were no significant adverse reactions in three groups. The recurrence rate of group A was 25%, no recurrence in Group B and C and the difference was statistically significant(<i>P</i><0.05).<p>CONCLUSION: Intravitreal ranibizumab or Conbercept combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion is effective. But injection times of Conbercept is less.
